Escolar Documentos
Profissional Documentos
Cultura Documentos
Management of Diabetes in
Low Resource Settings
• One son is drunkard who takes away the little income that they earn
**Davies MJ et al Real-world factors affecting adherence to insulin therapy in patients with type 1 or type 2 diabetes mellitus: a systematic review.
Diabetic Medicine. 2013;30(5):512–24. s than their peers without diabetes.
Drug Cost per tablet
GLICLAZIDE Rs.3.95
GLIMEPIRIDE Rs. 3.77
GLIPIZIDE Rs. 1.61
Introducing simple
Integrating Task sharing clinical monitoring
services at the
primary care
level
National Guideline
Diabetes Makers in
low
Programme income
Managers countries
Relief
NGOs
Workers
Recommendation1
Recommendation2
Second line medications
Third Line Medications
Recommendation 3
Recommendation 4 Recommendation 5
Strong recommendation
Moderate-quality evidence
Remarks::::
• Glibenclamide- Should be avoided in patients aged 60 years and older.
• Lack of RCTs on how each new drug class compares with all the others
(particularly new agents vs. old ones) and concluded that the evidence
reviewed did not convincingly show the superiority or inferiority of any one
class.
• New OHAs are currently substantially more expensive compared to
sulfonylureas, & the modest clinical benefit does not sufficiently
outweigh the current price difference in the context of a public health
approach.
Strong recommendation
Very-low-quality evidence
RECOMMENDATION 3
• If insulin is unsuitable*, a dipeptidyl peptidase-4 (DPP-4) inhibitor,
a sodium–glucose cotransporter-2 (SGLT-2) inhibitor, or a
thiazolidinedione (TZD) may be added
Weak recommendation
*(e.g. persons who live alone and are dependent on others to
Very-low-quality evidence inject them with insulin).
GUIDELINE GROUP thoughts::::
• Patient preference for newer oral agents was not deemed a
sufficiently strong reason to recommend them in the context of a
public health approach because the price of newer oral medicines is
currently higher than that of human insulin.
Strong recommendation
Low-quality evidence
Weak recommendation,
Moderate-quality evidence for severe hypoglycemia
weak recommendation reflecting the lack of, or very low-quality evidence for, any
of the long-term outcomes such as chronic diabetes complications and mortality,
and the considerable higher costs for long-acting insulin analogues compared to
intermediate-acting human insulin.
GUIDELINE GROUP thoughts::::